{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:32:48Z","timestamp":1793305968583,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008723","name":"Universidad de C\u00e1diz","doi-asserted-by":"publisher","award":["Ayudas Plan Propio UCA 2025-2027"],"award-info":[{"award-number":["Ayudas Plan Propio UCA 2025-2027"]}],"id":[{"id":"10.13039\/501100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2023-152388OA-I00"],"award-info":[{"award-number":["PID2023-152388OA-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["EMERGIA Grant EMC21-00041"],"award-info":[{"award-number":["EMERGIA Grant EMC21-00041"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jlr.2026.101144","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:05:41Z","timestamp":1789085141000},"page":"101144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roles of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the regulation of hepatic triglyceride metabolism"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3415-2819","authenticated-orcid":false,"given":"Daniel","family":"Palenque-Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-6434","authenticated-orcid":false,"given":"Michele","family":"Alves-Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2026.101144_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2026.101144_bib2","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101144_bib3","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101144_bib4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101144_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101144_bib6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101144_bib7","first-page":"418","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"10.1016\/j.jlr.2026.101144_bib8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101144_bib9","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101144_bib10","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of Proprotein Convertase Subtilisin\/Kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101144_bib11","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jlr.2026.101144_bib12","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101144_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2009.06.023","article-title":"Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles","volume":"208","author":"Norata","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2026.101144_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jacl.2018.04.004","article-title":"R46L polymorphism in the PCSK9 gene: relationship to lipid levels, subclinical vascular disease, and erectile dysfunction","volume":"12","author":"Mostaza","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jlr.2026.101144_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jlr.2026.101144_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jlr.2026.101144_bib17","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101144_bib18","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101144_bib19","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101144_bib20","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2026.101144_bib21","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101144_bib22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101144_bib23","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2026.101144_bib24","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1074\/jbc.275.12.8416","volume":"275","author":"Taghibiglou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2026.101144_bib25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1194\/jlr.M001966","article-title":"A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats","volume":"51","author":"Buqu\u00e9","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2026.101144_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jlr.2026.101144_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jlr.2026.101144_bib28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"key":"10.1016\/j.jlr.2026.101144_bib29","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis","volume":"1865","author":"Emma","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jlr.2026.101144_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.jlr.2026.101144_bib31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"Le May","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2026.101144_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","article-title":"Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis","volume":"77","author":"Paquette","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jlr.2026.101144_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113621","article-title":"Inhibition of hepatic PCSK9 as a novel therapeutic target ameliorates metabolic steatohepatitis in mice","volume":"143","author":"Mijiti","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jlr.2026.101144_bib34","article-title":"PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jlr.2026.101144_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12876-021-02041-8","article-title":"Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study","volume":"21","author":"Eshraghian","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.jlr.2026.101144_bib36","first-page":"321","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.jlr.2026.101144_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/JCI128650","article-title":"The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury","volume":"131","author":"Lebeau","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2026.101144_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/joim.12521","article-title":"Using human genetics to discover new therapeutic targets for plasma lipids","volume":"280","author":"Cohen","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jlr.2026.101144_bib39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3389\/fgene.2020.01020","article-title":"PCSK9 variants in familial hypercholesterolemia: a comprehensive synopsis","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.jlr.2026.101144_bib40","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2026.101144_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jlr.2026.101144_bib42","article-title":"PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes","volume":"13","author":"Zhou","year":"2026","journal-title":"Front. Med."},{"key":"10.1016\/j.jlr.2026.101144_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12986-023-00738-z","article-title":"High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes","volume":"20","author":"N\u00e9meth","year":"2023","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.jlr.2026.101144_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor","volume":"40","author":"Da Dalt","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2026.101144_bib45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/cvr\/cvw194","article-title":"Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering","volume":"112","author":"Norata","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jlr.2026.101144_bib46","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526001744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227526001744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:19:57Z","timestamp":1793305197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227526001744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022227526001744"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101144","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the regulation of hepatic triglyceride metabolism","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2026.101144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101144"}}